Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing data
Maaike van der Lee, William G. Allard, Rolf H. A. M. Vossen, Renée Baak-Pablo, Roberta Menafra, Birgit Deiman, Maarten J. Deenen, Patrick Neven, Inger Johansson, Stefano Gastaldello, Magnus Ingelman‐Sundberg, Henk‐Jan Guchelaar, Jesse J. Swen, Seyed Yahya Anvar
Abstract
adjusted = 0.55). Human embryonic kidney cells were used to confirm the effect of five genetic variants on metabolism of the CYP2D6 substrate bufuralol in vitro. These results demonstrate the advantage of a continuous scale and a completely phased genotype for prediction of CYP2D6 enzyme activity and could potentially enable more accurate prediction of individual drug response.
Topics & Concepts
CYP2D6TamoxifenGeneBiologyComputational biologyPharmacogenomicsPharmacologyGeneticsGenotypeCancerBreast cancerPharmacogenetics and Drug MetabolismInflammatory mediators and NSAID effectsStatistical Methods in Clinical Trials